EP3906025A4 - Topical formulations having cannabinoid - Google Patents

Topical formulations having cannabinoid Download PDF

Info

Publication number
EP3906025A4
EP3906025A4 EP20736215.3A EP20736215A EP3906025A4 EP 3906025 A4 EP3906025 A4 EP 3906025A4 EP 20736215 A EP20736215 A EP 20736215A EP 3906025 A4 EP3906025 A4 EP 3906025A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoid
topical formulations
topical
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20736215.3A
Other languages
German (de)
French (fr)
Other versions
EP3906025A1 (en
Inventor
Aaron Michael DELY
Shaun BEN-ARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia Care LLC
Original Assignee
Columbia Care LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Care LLC filed Critical Columbia Care LLC
Publication of EP3906025A1 publication Critical patent/EP3906025A1/en
Publication of EP3906025A4 publication Critical patent/EP3906025A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/04—Skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP20736215.3A 2019-01-04 2020-01-03 Topical formulations having cannabinoid Withdrawn EP3906025A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962788494P 2019-01-04 2019-01-04
PCT/US2020/012187 WO2020142692A1 (en) 2019-01-04 2020-01-03 Topical formulations having cannabinoid

Publications (2)

Publication Number Publication Date
EP3906025A1 EP3906025A1 (en) 2021-11-10
EP3906025A4 true EP3906025A4 (en) 2022-09-21

Family

ID=71406979

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20736215.3A Withdrawn EP3906025A4 (en) 2019-01-04 2020-01-03 Topical formulations having cannabinoid

Country Status (2)

Country Link
EP (1) EP3906025A4 (en)
WO (1) WO2020142692A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
MX2023000314A (en) * 2020-08-17 2023-02-22 Pike Therapeutics Inc Transdermal pharmaceutical formulations of cannabinoids.
WO2022217147A1 (en) * 2021-04-09 2022-10-13 Rosenfeld Mark J Methods for improving cutaneous permeation of cannabinoids and fatty acid amides
CN113244410A (en) * 2021-05-28 2021-08-13 哈尔滨工业大学 Preparation method of clathrate compound based on porous starch and used for increasing cannabidiol water solubility

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200049A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US20160309774A1 (en) * 2015-04-27 2016-10-27 Michael D. Wand Terpene carrier
WO2018023164A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
WO2018236957A1 (en) * 2017-06-20 2018-12-27 Nexien Biopharma, Inc. Method and compositions for treating restless legs syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
CA3023049A1 (en) * 2016-05-04 2017-11-09 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
BR112018075073A2 (en) * 2016-06-02 2019-04-30 Acerus Pharmaceutical Corporation cannabidiol nasal compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200049A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US20160309774A1 (en) * 2015-04-27 2016-10-27 Michael D. Wand Terpene carrier
WO2018023164A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
WO2018236957A1 (en) * 2017-06-20 2018-12-27 Nexien Biopharma, Inc. Method and compositions for treating restless legs syndrome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHERNIAKOV IRINA ET AL: "Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 266, 8 September 2017 (2017-09-08), pages 1 - 7, XP085292686, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.09.011 *
P K LAKSHMI ET AL: "OILS AS PENETRATION ENHANCERS FOR IMPROVED TRANSDERMAL DRUG DELIVERY: A REVIEW", INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, vol. 8, no. 4, 30 May 2017 (2017-05-30), pages 9 - 17, XP055949663, Retrieved from the Internet <URL:http://www.irjponline.com/admin/php/uploads/2645_pdf.pdf> DOI: 10.7897/2230-8407.080440 *
See also references of WO2020142692A1 *

Also Published As

Publication number Publication date
EP3906025A1 (en) 2021-11-10
WO2020142692A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
EP3703672A4 (en) Cannabinoid formulations
EP3735240A4 (en) Solid self-emuslifying cannabinoid compositions
GB2584341B (en) Cannabinoid formulations
EP3746086A4 (en) Topical formulations comprising tofacitinib
EP3994114A4 (en) Cannabinoid derivatives
EP3906025A4 (en) Topical formulations having cannabinoid
EP3615079A4 (en) Stable cannabinoid formulations
EP3997098A4 (en) Cannabinoid derivatives
EP3746043A4 (en) Topical compositions
EP3946315A4 (en) Cannabinoid compositions and use thereof
EP4121020A4 (en) Cannabinoid compositions
EP4037676A4 (en) Cannabinoid derivatives
EP4038058A4 (en) Cannabinoid derivatives
EP3999490A4 (en) Cannabinoid derivatives
EP3876907A4 (en) Suppository formulations having cannabinoid
EP4034100A4 (en) Cannabinoid prodrug compounds
EP3817750A4 (en) Cannabidiol combination compositions
EP4073033A4 (en) Cannabinoid derivatives
EP4065549A4 (en) Cannabinoid derivatives
EP3997069A4 (en) Cannabinoid derivatives
EP3997095A4 (en) Cannabinoid derivatives
EP3994129A4 (en) Cannabinoid derivatives
EP4073053A4 (en) Cannabinoid derivatives
EP4065568A4 (en) Cannabinoid derivatives
EP4110045A4 (en) Cannabinoid compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210803

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220819

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 11/00 20060101ALI20220812BHEP

Ipc: A61P 17/00 20060101ALI20220812BHEP

Ipc: A61P 35/00 20060101ALI20220812BHEP

Ipc: A61P 25/00 20060101ALI20220812BHEP

Ipc: A61K 38/48 20060101ALI20220812BHEP

Ipc: A61K 36/81 20060101ALI20220812BHEP

Ipc: A61K 9/12 20060101ALI20220812BHEP

Ipc: A61K 9/00 20060101ALI20220812BHEP

Ipc: A61K 36/67 20060101ALI20220812BHEP

Ipc: A61K 36/185 20060101ALI20220812BHEP

Ipc: A61K 31/05 20060101ALI20220812BHEP

Ipc: A61K 31/352 20060101AFI20220812BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230303